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To the Editor: As a response to claims that pharmaceutical 
industry, ie, “PharmaNostra,” was preventing market access 
to generic producers, European Commission for Competi-
tion launched a thorough investigation. In July 2009, after 
more than a year of investigation, Neelie Kroes, European 
Commissioner for Competition, published a comprehen-
sive report, painting an alarming picture of antitrust be-
havior of pharmaceutical industry (innovators) (1).
Such outcome presents a challenge for the European 
Commission, which is supposed create an ideal business 
environment for pharmaceutical multinationals and at the 
same time ensure access to medicines for all.
PharmaNostra, to cover the costs of research on new 
drugs, requires generous patent protection. Patenting new 
drugs creates a monopoly for innovators, with artificially 
high prices and limited affordability of medicines. By ad-
mitting generic medicines (ie, patent-expired medicines) 
to the pharmaceutical market, PharmaNostra’s monopoly 
will be annulled, with lower prices as a result. However, 
PharmaNostra’s unpleasant role of hindering market ac-
cess to generic producers makes medicines unnecessarily 
expensive. Since most prescription medicines are financed 
by social health insurance, it is in the interest of European 
Union member states to achieve low prices.
OutcOme Of sectOr research
To protect its market share, PharmaNostra makes use of 
several controversial techniques. Effective delay tactics in-
clude “infringement of patent” litigation procedures against 
generic companies and customers (hospitals and pharma-
cies), despite patent expirations which make the allegation 
unfounded. Due to deliberate deception, competitors and 
customers will subsequently abstain from “patent infringe-
ments.” This tactic is open for judicial review, but this takes 
a considerable amount of time (3 years on average), which 
will help PharmaNostra delay market access to generic 
products. And when it comes to “blockbusters” − products 
with a market value of several billion Euros − every month 
of delay is crucial.
Another method involves the agreement between Phar-
maNostra and generic manufacturers to pay the generic 
manufacturers compensation for postponing market par-
ticipation. Parties will share the monopoly profit as a result. 
Such patent payment agreements hamper free competi-
tion and harm consumers. When parties cannot agree on 
the level of compensation, acquisition by PharmaNostra is 
an alternative. Thus, the new owner acquires control of the 
introduction of the new generic medicine.
Other interventions focus on national authorization of 
generic medicines. Authorization is a prerequisite for all 
medicines prior to market access. One of PharmaNostra's 
delay tactics is challenging such registration, while hold-
ing registration authorities liable for a “breach of patent.” 
During the subsequent legal proceedings, a majority of 
such claims will be withdrawn, allowing authorization and 
therefore market access, but with a considerable delay. A 
similar practice occurs when local authorities are involved 
in healthcare package decision-making.
Finally, prior to patent expiration, PharmaNostra may de-
cide to introduce a “second generation” medicine. Put sim-
ply, rather than in powder form, the “new” drug will then be 
offered in a tablet form, thereby extending patent rights.
Where tO gO?
The examples confirm PharmaNostra’s reputation as a 
group of unscrupulous entities without any social respon-
sibility. This is also confirmed by the 2008 report of United 
Nation’s Special Reporter on Health, which formulated the 
guidelines on PharmaNostra’s role in achieving global ac-
cess to medicines (2). As early as in the consultation stage, 
major pharmaceutical companies failed to cooperate 
and rejected responsibilities as formulated by the Unit-
ed Nations guidelines. Apparently, it is PharmaNos-
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tra that determines the need and necessity for the intro-
duction of new medicines and its timing.
Recognition of its social responsibility by upholding United 
Nations guidelines on essential medicines is a step in the 
right direction. Without doubt, the pharmaceutical market 
cannot survive without such ethical imperatives. Abuse of 
property rights as identified in the Commission’s report (1) 
should be sanctioned and patients’ rights require protec-
tion. In addition, Member States should speed up the in-
troduction of a so-called “European patent,” replacing the 
current combination of 27 national patents. Supposed pat-
ent breaches can be exclusively reviewed by the European 
Patent Court (European Court of Justice), which will im-
prove the quality of patents and avoid unnecessary delay.
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